Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heather H Cheng

Showing results (61-70 of 141) with videos related to

Pageof 15
Sort By:
Plos One|June 2, 2018
A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancerMichael T Schweizer, Kathleen Haugk, Jožefa S McKiernan, et al.
Plos One|August 16, 2018
Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancerMichael T Schweizer, Kathleen Haugk, Jožefa S McKiernan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2025
Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO GuidelineEvan Y Yu, R Bryan Rumble, Neeraj Agarwal, et al.
Oncotarget|October 21, 2016
Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostateMichael T Schweizer, Heather H Cheng, Maria S Tretiakova, et al.
Plos One|August 13, 2013
Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxiaHeather H Cheng, Patrick S Mitchell, Evan M Kroh, et al.
BJU International|June 10, 2026
The 'Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease' (PATROL) studyHeather H Cheng, Kara N Maxwell, Keyan Salari, et al.
JCO Precision Oncology|January 9, 2023
Internet-Based Germline Genetic Testing for Men With Metastatic Prostate CancerHeather H Cheng, Alexandra O Sokolova, Roman Gulati, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 14, 2024
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received <sup>177</sup>Lu-PSMA-617: Importance of <sup>18</sup>F-FDG-Avid Discordant FindingsRidvan Arda Demirci, Alireza Ghodsi, Roman Gulati, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2021
Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate CancerElahe A Mostaghel, Brett T Marck, Orpheus Kolokythas, et al.
Clinical Genitourinary Cancer|June 21, 2023
Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy StudyFady Ghali, Funda Vakar-Lopez, Martine P Roudier, et al.
Pageof 15

Showing results (61-70 of 141) with videos related to

Sort By:
Pageof 15
Plos One|June 2, 2018
A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancerMichael T Schweizer, Kathleen Haugk, Jožefa S McKiernan, et al.
Plos One|August 16, 2018
Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancerMichael T Schweizer, Kathleen Haugk, Jožefa S McKiernan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2025
Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO GuidelineEvan Y Yu, R Bryan Rumble, Neeraj Agarwal, et al.
Oncotarget|October 21, 2016
Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostateMichael T Schweizer, Heather H Cheng, Maria S Tretiakova, et al.
Plos One|August 13, 2013
Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxiaHeather H Cheng, Patrick S Mitchell, Evan M Kroh, et al.
BJU International|June 10, 2026
The 'Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease' (PATROL) studyHeather H Cheng, Kara N Maxwell, Keyan Salari, et al.
JCO Precision Oncology|January 9, 2023
Internet-Based Germline Genetic Testing for Men With Metastatic Prostate CancerHeather H Cheng, Alexandra O Sokolova, Roman Gulati, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 14, 2024
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received <sup>177</sup>Lu-PSMA-617: Importance of <sup>18</sup>F-FDG-Avid Discordant FindingsRidvan Arda Demirci, Alireza Ghodsi, Roman Gulati, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2021
Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate CancerElahe A Mostaghel, Brett T Marck, Orpheus Kolokythas, et al.
Clinical Genitourinary Cancer|June 21, 2023
Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy StudyFady Ghali, Funda Vakar-Lopez, Martine P Roudier, et al.
Pageof 15